Cetermin

Drug Profile

Cetermin

Alternative Names: Betakine; Recombinant transforming growth factor-beta-2; TGF-beta-2; Transforming growth factor-beta-2

Latest Information Update: 15 Dec 2016

Price : $50

At a glance

  • Originator Insmed
  • Developer Enzon Pharmaceuticals; Genzyme Corporation; Insmed
  • Class Transforming growth factors
  • Mechanism of Action Immunosuppressants; Intercellular signalling peptide and protein stimulants; Osteogenesis stimulants; Transforming growth factor beta2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Age-related macular degeneration; Autoimmune disorders; Cancer; Diabetic foot ulcer; Eye disorders; Multiple sclerosis; Pleural effusion; Postmenopausal osteoporosis; Rheumatoid arthritis; Skin disorders; Transplant rejection

Most Recent Events

  • 10 Jan 2006 Discontinued - Phase-I for Multiple sclerosis in USA (IV)
  • 10 Jan 2006 Discontinued - Phase-II for Diabetic foot ulcer in USA (unspecified route)
  • 10 Jan 2006 Discontinued - Preclinical for Pleural effusion in Australia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top